

ASTCT Pharmacy SIG Journal Club Session

June 11, 2025

2:00-3:00 PM CDT

TARGET AUDIENCE

This session is intended for pharmacists and other members of the health care team who are involved in managing patients undergoing hematopoietic stem cell transplantation.

PROGRAM OVERVIEW

This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q & A session. In the *June Journal Club* session, Drs. Aljundi and Henderson will present two articles related to:

- a. Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation
- b. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy

LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

- Review current standard of care approaches to GVHD prophylaxis in the haploidentical transplant setting
- Analyze safety and efficacy of itacitinib prophylaxis for prevention of GVHD and CRS in haploidentical transplant
- Assess feasibility and functionality of implementation of itacitinib prophylaxis in haploidentical transplant.
- Review the pathophysiology of Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease (PTLD) and the clinical challenges associated with its management in hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients
- Analyze the safety and efficacy outcomes of tabelecleucel for the treatment of relapsed or refractory EBV-positive PTLD
- Evaluate the role of tabelecleucel as a treatment option for patients with EBV-positive PTLD in both relapsed/refractory and future frontline settings

FACULTY & ARTICLES

Alisar Aljundi, PharmD

PGY-2 Pharmacy Resident

Barnes-Jewish Hospital

Article: [Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation](#)

Jonathan Henderson, PharmD

PGY-2 Pharmacy Resident

Baylor University Medical Center

Article: [Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy \(ALLELE\): a phase 3, multicentre, open-label trial](#)

Instructions for Participation and Requesting Credit

There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the activity, and completing the posttest and evaluation form. A score of at least 75% on the posttest is required to successfully complete this activity. The participant may take the test until successfully passed.

Credit Fulfillment

- If you are a pharmacist requesting ACPE credits, your credit request will be uploaded to CPE Monitor within 60 days

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists



This knowledge-based activity, UAN JA0007204-9999-25-059-L01-P, qualifies for 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. **Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date.** Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

All other healthcare professionals completing this course will be issued a statement of participation.

DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity,

balance, and scientific rigor in all of their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Disclosures

The individuals listed below disclosed the following relevant financial relationships:

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Alisar Aljundi, PharmD	Faculty	No relevant financial disclosures	N/A	N/A
Ashley Smeaton, MHA	TFF Staff	No relevant financial disclosures	N/A	N/A
Elizabeth Eubanks, PharmD, BCOP	Reviewer/Mentor	1. Medexus Pharmaceuticals, Inc., Dedham Group	1. Non-CE Consulting	The following relationships were mitigated by: <ul style="list-style-type: none"> Medexus Pharmaceuticals ended 5/25/22 Dedham Group ended 3/24/23
Erin Eberwein, PharmD, BCOP	Reviewer/Mentor	No relevant financial disclosures	N/A	N/A
Haedyn Smith	ASTCT Staff	No relevant financial disclosures	N/A	N/A
Jade Braun, PharmD	Reviewer/Mentor	No relevant financial disclosures	N/A	N/A
Jonathan Henderson, PharmD	Faculty	No relevant financial disclosures	N/A	N/A
Justin Tossey, PharmD, BCOP	Reviewer/Mentor	1. BioLineRx, USA, Inc.	1. Non-CE Consulting	The following relationship was mitigated by: <ul style="list-style-type: none"> BioLineRx, USA, Inc. ended 12/28/24
Katelyn Yamartino, PharmD	Reviewer/Mentor	No relevant financial disclosures	N/A	N/A

Pearl Abraham, PharmD, BCPS, BCOP	Reviewer/Mentor	No relevant financial disclosures	N/A	N/A
---	-----------------	-----------------------------------	-----	-----

DISCLOSURE OF UNLABELED USE

TFF and ASTCT require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

DISCLAIMER

TFF and ASTCT present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and ASTCT assume no liability for the information herein.

CONTACT INFORMATION

If you have questions about this CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.